Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v11-EN Version v10-FR
Language English French
Date Updated 2020-04-25 2020-04-24
Drug Identification Number 02241889 02241889
Brand name ARAVA 20 MG ARAVA 20 MG
Common or Proper name Arava Arava
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients LEFLUNOMIDE LEFLUNOMIDE
Strength(s) 20MG 20MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 30 30
ATC code L04AA L04AA
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for shortage Shortage of an active ingredient. Shortage of an active ingredient.
Anticipated start date
Actual start date 2020-03-27 2020-03-27
Estimated end date 2020-04-24 2020-04-24
Actual end date 2020-04-24 2020-04-24
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments